.
Malaria. Plasmodium falciparum. Protein expression. Protein purification. Shikimate dehydrogenase.
Plasmodium falciparum is known to cause severe malaria. Current treatment consists in artemisinin-based combination therapy, but resistance can lead to treatment failure. The knowledge of essential proteins of P. falciparum can be used on the search for new antimalarials, among these is shikimate dehydrogenase (SDH), part of a pathway responsible for the production of endogenous aromatic amino acids. SDH from P. falciparum (PfSDH) is unknown to the scientific community, therefore, this study aims to establish the first protocol for active PfSDH expression. Putative PfSDH nucleotide sequence was used to construct the optimized expression vector pET28a+PfSDH inserted in E. coli BL21(DE3). Optimal expression conditions were acquired by varying IPTG and time while temperature was fixed at 37 °C. Western Blot analysis was applied to verify appropriate PfSDH expression. Solubilization and purification started with lysis followed by double IMAC purification. SDS-PAGE was applied over various steps. Enzyme activity was measured spectrophotometrically by NADPH oxidation. Tanimoto coefficient and pharmacophore pattern similarity were applied to the in silico search for ligands employing the substrate DHS as template. Optimal PfSDH expression occur at 0.1 mM IPTG for 48 hours of growth at 37 °C and shaking at 200 rpm. Recombinant PfSDH obtained after purification was soluble, pure and its physiological catalysis was confirmed. Among all possible ligands obtained, 15 molecules had greater relevance when combining both methods applied. Thus, this study describes the first protocol for heterologous expression of PfSDH in soluble and active form, likewise instigating for a higher comprehension related to target-ligant interactions.